EBV-immortalized memory B cells derived from ZIKV-infected, DENV-naive human donors.
The main route of Zika Virus (ZIKV) infection is through bites by Aedes mosquitos, but the virus may also be sexually and vertically transmitted. Although most of the ZIKV infections are asymptomatic or cause only mild symptoms, there is evidence that ZIKV infection can lead to neurological complications, such as Guillain-Barre syndrome in adults and congenital birth defects, including microcephaly in the developing fetus, likely through its ability to infect human neural progenitor cells. Whereas flavivirus envelope (E) proteins mediate fusion and are the main target of neutralizing antibodies, the non-structural protein 1 (NS1) is secreted by infected cells and is involved in immune evasion and pathogenesis. The E protein contains three domains: EDI involved in the conformational changes required for viral entry, EDII containing the fusion loop, and EDIII which may be involved in binding to cellular receptors. The best specific neutralizing antibodies to ZIKV are directed against the domain EDIII of ZIKV. Applications: Suitable for use in Neutralization. Other applications not tested. Recommended Dilutions: Neutralization: Neutralizes Zika Virus (ZIKV) with an IC50 of ~93ng/ml. Also enhances ZIKV infection in non-permissive K562 cells at a broad range of concentrations (not above 1ug/ml). Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Klonalität:
Monoclonal
Klon-Bezeichnung:
[ZKA64]
Reinheit:
95% (SDS-PAGE). Endotoxin: 0.001EU/ug.
Formulierung:
Supplied as a liquid in PBS. No preservative added.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
